EURACTIV PR

An easy way of publishing your relevant EU press releases.

eSMART Consortium holds final conference in Brussels

Date

05 Jul 2019

Sections

Health & Consumers
Brussels 5 July 2019.
 
In the wake of an already devastating cancer diagnosis, European cancer patients often grapple with debilitating symptoms and side effects.  
 
For these patients, the eSMART (Electronic Symptom Management System Remote Technology) trial provides new hope for improved management of the side effects and symptoms of cancer, and with it, improved quality of life.
 
Today, the eSMART (Electronic Symptom Management System Remote Technology) Consortium presented its preliminary results at a conference in Brussels.
 
eSMART uses a mobile phone based remote monitoring system  called the Advanced Symptom Management System (ASyMS). ASyMS monitors symptoms of people with cancer in real time in their homes and reports those of concern to their hospital team.  
 
In this study over 800 people with breast, colorectal, and haematological cancers having chemotherapy across 12 hospitals in Greece, the UK, Ireland, Austria and Norway took part in a trial evaluating its clinical and economic benefits. Chemotherapy can carry significant risk as people can become unwell very quickly. ASyMS can detect symptoms early and ensure rapid access to care as and when required.
 
Early results suggest that eSMART was highly successful in reducing chemotherapy symptoms. It augmented cancer care services in these countries by promoting a move from reactive to anticipatory models of care. Such models of care can prevent costly hospitalisation and result in cost savings.  eSMART’s results are providing important evidence of mHealth’s potential  clinical and economic benefits—benefits poised to be multiplied when the solutions are deployed at scale.
 
Kathi Apostolidis, President of Consortium-member European Cancer Patients Coalition (ECPC), said:  “eSMART demonstrates that digital tools delivering patient-focused, anticipatory care can be important for patients’ quality of life,” said.
 
“Better symptom management puts the patient back in control of their lives and their disease. It is also advantageous for healthcare systems as it helps patients to stay well at home for as long as possible, thereby preventing costly hospital admissions and inappropriate service use.” 
 
The eSMART Consortium was led by the University of Strathclyde Glasgow and was funded by the EU’s 7th Framework Programme for Research and Innovation (FP7).
 
Professor Roma Maguire from the University of Strathclyde Glasgow who is the Chief Investigator for this study, said: “Projects like eSMART showcase what we can achieve when we pool our European expertise and resources.
 
“For this reason I am delighted to have led this innovative and collaborative project that focuses on safety and quality of care. These are so important to all people with cancer across Europe and directly enhance their quality of life”. 
 
ENDS
 
ABOUT eSMART
 
eSMART was financed under FP7, the 7th EU Framework Programme for Research and Innovation (2007 – 2013). The Consortium, led by the University of Strathclyde Glasgow, brought together EU and US-American university medical centres (University of Surrey (UK), University of Athens (GR), King's College London (UK), University of Dundee (UK), Medical University of Vienna (AT), University College Dublin (IR), University of California, San Francisco (US), Sykehuset Innlandet Hospital (NO), NHS24 (UK)), the European Cancer Patient Coalition and technology company Docobo Ltd.

Jobs

CEEP - European Centre of Employers and Enterprises providing public services
Policy Officer
Hanover Communication
Healthcare Policy Internship
Sandemans New Europe
Promoter
European Food Information Council aisbl (EUFIC)
Communications Manager
IDEX Accelerator
IDEX Fellowship
EUFAMI - European Federation of Associations of Families of People with Mental Illness
Executive Director
Cosmetics Europe
Communications Manager
Finabel - European Army Interoperability Centre
Communication Trainee